List of Excipients in Branded Drug HYDREA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	HYDREA	hydroxyurea	0003-0830	CITRIC ACID MONOHYDRATE
ER Squibb & Sons LLC	HYDREA	hydroxyurea	0003-0830	D&C RED NO. 28
ER Squibb & Sons LLC	HYDREA	hydroxyurea	0003-0830	D&C YELLOW NO. 10
ER Squibb & Sons LLC	HYDREA	hydroxyurea	0003-0830	FD&C BLUE NO. 1
ER Squibb & Sons LLC	HYDREA	hydroxyurea	0003-0830	FD&C RED NO. 40

HYDREA Excipient Strategy and Commercial Opportunities for Hydroxyurea

Last updated: August 21, 2026

Hydrea is the original branded hydroxyurea product, approved in the United States as a 500 mg oral capsule. Its excipient profile is simple and largely commoditized: lactose, sodium phosphate dibasic, citric acid, and magnesium stearate, with a hard-gelatin capsule shell. The core commercial opportunity is not a new Hydrea patent position. It is the development of differentiated hydroxyurea dosage forms that address pediatric dosing, swallowing difficulty, excipient intolerance, hazardous-drug handling, stability, and adherence.

Hydroxyurea has no meaningful current composition-of-matter exclusivity. Generic hydroxyurea products have been marketed for decades. Commercial differentiation therefore depends on formulation performance, regulatory execution, supply reliability, and targeted clinical use rather than broad patent protection.

What is Hydrea and how is its formulation positioned?

Hydrea contains hydroxyurea, an antineoplastic and antimetabolite drug used in conditions including chronic myeloid leukemia, head and neck cancers, and sickle cell disease. The U.S. product is a 500 mg capsule administered orally.[1]

Attribute	Hydrea profile
Active ingredient	Hydroxyurea
Dosage form	Hard gelatin capsule
Strength	500 mg
U.S. regulatory product	NDA 016295
Original sponsor	Bristol-Myers Squibb predecessor companies
Current market structure	Brand plus multiple generic hydroxyurea products
Key labeled excipients	Lactose, sodium phosphate dibasic, citric acid, magnesium stearate
Capsule shell	Gelatin-based shell with colorants and printing ink
Therapeutic categories	Antineoplastic therapy; sickle cell disease
Primary formulation constraints	Cytotoxic handling, dose flexibility, swallowing, stability, pediatric administration

The formulation is technically conventional. Lactose provides bulk, sodium phosphate dibasic and citric acid support the formulation environment, and magnesium stearate functions as a lubricant. The capsule shell provides a low-cost oral presentation but limits flexibility for patients who cannot swallow capsules or require doses below 500 mg.

Hydroxyurea is a low-molecular-weight, water-soluble active pharmaceutical ingredient. Its formulation challenge is less about solubilization than about dose accuracy, chemical stability, exposure control, administration convenience, and safe handling.

What excipients are used in Hydrea capsules?

The Hydrea prescribing information identifies lactose, sodium phosphate dibasic, citric acid, and magnesium stearate as inactive ingredients.[1] The capsule shell contains gelatin and colorants. Exact shell composition and imprinting components should be confirmed against the current product label and manufacturer-specific packaging.

Functional role of the Hydrea excipients

Excipient	Likely formulation function	Commercial implication
Lactose	Diluent and capsule-fill bulking agent	Creates an opportunity for lactose-free or low-lactose alternatives
Sodium phosphate dibasic	Buffering or pH-control component	Relevant to solution stability and oral-liquid development
Citric acid	Acidulant and pH modifier	May support chemical stability but can affect taste and compatibility
Magnesium stearate	Lubricant for powder processing	Standard, low-cost excipient with limited differentiation value
Gelatin	Capsule-shell structural material	Creates vegetarian, allergen, and swallowing-positioning opportunities
Titanium dioxide or colorants, where used	Capsule appearance and identification	Potential target for colorant-reduced products

The commercial value of these excipients is limited in the legacy capsule. A generic manufacturer can generally source them from qualified suppliers without creating a differentiated market position. The more defensible opportunities arise when excipient selection enables a new route of administration, a new patient population, or a measurable stability and safety advantage.

What excipient strategies can differentiate hydroxyurea products?

The strongest strategy is to move beyond the 500 mg capsule while preserving low manufacturing complexity.

Lactose-free hydroxyurea

Lactose-free development could target patients with lactose intolerance, dietary restrictions, or sensitivity to lactose-containing medicines. The regulatory benefit is likely to be limited because lactose is not generally a barrier to hydroxyurea use. The commercial benefit would depend on payer access, institutional procurement, and evidence that the product solves a practical problem.

Potential replacement diluents include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected starch-based systems. The choice would need to account for powder flow, content uniformity, capsule-fill weight, dissolution, and compatibility with hydroxyurea.

A lactose-free capsule is unlikely to support a strong standalone premium unless paired with another benefit, such as lower capsule size, improved stability, or a pediatric dosing system.

Vegetarian or non-gelatin capsules

A hydroxyurea capsule using hypromellose or another non-gelatin shell could address institutional and dietary preferences. This is a low-complexity change, but it usually provides weak intellectual-property protection. The commercial case is strongest in hospital formularies, international markets with vegetarian positioning, and products seeking simplified excipient declarations.

The strategy is commercially more credible when combined with colorant reduction, tamper-evident unit packaging, or a smaller capsule presentation.

Pediatric oral liquid

An oral liquid is the highest-value excipient opportunity. Children with sickle cell disease often require weight-based doses that do not correspond to a 500 mg capsule. A liquid can reduce dose-rounding problems and eliminate the need to manipulate capsules.

The formulation must address:

• Hydroxyurea concentration and dose accuracy
• Chemical and microbiological stability
• Palatability and taste masking
• Preservative compatibility
• Syringe-based dose measurement
• Cytotoxic-drug handling
• Cleaning and disposal instructions
• Container closure and light protection
• Stability after opening

Possible vehicles include aqueous solutions, suspensions, and ready-to-use or pharmacy-prepared systems. A true solution may offer dose uniformity advantages, but taste and chemical stability can be more difficult. A suspension can improve stability in some systems but creates redispersion and dose-uniformity requirements.

Taste masking is commercially important because hydroxyurea can be difficult for children to accept. Sweeteners, flavors, viscosity modifiers, and buffering agents can improve administration, but each adds regulatory and stability considerations. The product should avoid excipients that create avoidable risks for neonates, young children, or patients with renal impairment.

A pediatric liquid can support method-of-use, device, packaging, and formulation claims even though the hydroxyurea molecule is unprotected.

Sprinkle or capsule-opening presentation

A capsule designed to be opened and sprinkled onto soft food could offer a lower-cost alternative to a liquid. This approach requires evidence that opening the capsule does not create unacceptable occupational exposure, content-uniformity problems, or loss of dose.

Hydroxyurea is a hazardous drug under occupational-exposure frameworks. The National Institute for Occupational Safety and Health lists hazardous-drug handling concerns for antineoplastic agents, and institutional procedures may discourage opening capsules outside controlled settings.[2] A sprinkle product would therefore need a carefully designed handling protocol, protective packaging, and clear administration instructions.

The opportunity is real but carries greater safety and regulatory complexity than simply changing the capsule excipients.

What formulations are protected by Hydrea patents?

Hydrea itself does not have a commercially relevant active patent estate. The original hydroxyurea product was approved in the 1960s, and any foundational composition or early formulation patents have expired.[1,3]

Protection category	Current commercial relevance
Hydroxyurea composition of matter	Expired
Original Hydrea capsule formulation	No meaningful current exclusivity
500 mg capsule presentation	Generic competition established
Pediatric oral liquid	Potentially protectable through formulation, packaging, device, or use claims
Modified-release hydroxyurea	Potential new patent opportunity, but development risk is high
Taste-masked formulation	Potential formulation claims, usually narrow
Hazard-control packaging	Potential device or packaging claims
Dosing syringe or administration kit	Potential combination-product or device claims
Sickle-cell treatment method	Possible method-of-use claims, but patentability depends on claim scope and prior art

Any new patent strategy should focus on a specific technical result. Broad claims covering hydroxyurea plus routine excipients would face substantial obviousness and enablement risk. More defensible claims may cover a defined concentration range, stability profile, preservative system, reconstitution protocol, container closure, or integrated dosing device.

What is the Orange Book status of Hydrea?

Hydrea is listed in FDA drug databases as an approved prescription product, but its historical approval does not create current market exclusivity. The Orange Book is relevant for determining listed patents and reference-product status, while FDA product labeling and Drugs@FDA provide the principal regulatory record.[3,4]

Does Hydrea have active Orange Book patents?

A current Orange Book review is required for transaction or litigation diligence because listed patent data can change. The commercial conclusion is clear: generic hydroxyurea competition is established, and Hydrea does not operate as a product protected by an active composition patent or a modern exclusivity period.

The relevant market risks are therefore not conventional paragraph IV attacks on a strong branded patent estate. They are:

• Generic substitution and price erosion
• Supply interruptions
• Product recalls
• Changes in hospital purchasing contracts
• Shortages of suitable capsule components or API
• Competition from alternative hydroxyurea products such as tablets or oral liquids
• Regulatory scrutiny of pharmacy-compounded liquids

When did Hydrea lose exclusivity?

Hydrea lost practical market exclusivity many years ago. Its initial U.S. approval predates the modern Hatch-Waxman framework, and generic hydroxyurea products have been available for an extended period.[1,3]

Milestone	Approximate status
Original U.S. approval	1960s
Foundational patent protection	Expired decades ago
Modern NCE exclusivity	Not applicable to the original product
Generic competition	Established
Current brand defense	Limited to branding, supply, contracts, and any product-specific listings
Commercial focus	Formulation differentiation and manufacturing economics

There is no credible scenario in which a new excipient supplier obtains broad exclusivity over the established Hydrea capsule. The opportunity is to develop a new hydroxyurea product with separate regulatory and patent characteristics.

Which companies are challenging or competing with Hydrea?

Competition comes from generic manufacturers rather than a concentrated branded challenger group. FDA-approved hydroxyurea products have included capsules and tablets marketed by multiple generic companies. Siklos, an oral tablet formulation of hydroxyurea, has provided a differentiated presentation for sickle cell disease, particularly where tablet strength and dosing flexibility are relevant.[5]

Droxia, another hydroxyurea product, has also occupied a differentiated branded position in sickle cell disease.[6] The competitive landscape includes:

Competitor type	Commercial advantage	Excipient opportunity
Generic 500 mg capsules	Low cost and established supply	Low
Hydroxyurea tablets	Potentially easier dose adjustment	Moderate
Pediatric oral liquids	Weight-based dosing and swallowing advantage	High
Pharmacy-compounded liquids	Local availability and customization	High risk for consistency
Modified-release products	Potential adherence benefit	High development cost
Combination packaging systems	Handling and dosing support	Moderate to high

Manufacturer-specific market shares and revenue exposure are not reliably inferable from the Hydrea label alone. Brand revenue is likely less important than the total hydroxyurea market and the institutional demand for reliable supply.

What generic entry risks exist for Hydrea?

Generic entry is already a structural feature of the market. The principal risk for any new product is not entry by a first generic but rapid price competition after approval.

A differentiated product can reduce that exposure by targeting an under-served segment:

1. Pediatric sickle cell disease.
2. Patients unable to swallow capsules.
3. Patients requiring doses below 500 mg.
4. Health systems requiring standardized hazardous-drug handling.
5. Patients needing lactose-free or non-gelatin formulations.
6. Markets where oral-liquid availability is limited.

The product should avoid competing solely on the 500 mg capsule because that segment is vulnerable to commodity pricing. A liquid, dose-flexible tablet, or administration kit offers more commercial separation.

How strong is the patent estate for a new hydroxyurea excipient product?

Patent strength would depend on the technical specificity of the product.

Product concept	Expected patent strength	Main risk
Lactose-free capsule	Low	Routine substitution of a diluent
Non-gelatin capsule	Low to moderate	Predictable shell substitution
Taste-masked pediatric liquid	Moderate	Prior art and obviousness
Stable ready-to-use liquid	Moderate to strong if stability is unexpected	Proof of stability and enablement
Unit-dose oral liquid syringe	Moderate	Device and packaging overlap
Modified-release hydroxyurea	Moderate to strong	Clinical and bioequivalence burden
Cytotoxic-safe administration kit	Moderate	Combination-product classification
Novel co-formulation	Potentially strong	Compatibility and clinical evidence requirements

A patent portfolio should combine formulation claims with manufacturing, container-closure, dosing-device, and method-of-use claims. A single excipient claim is unlikely to provide durable protection.

What manufacturing and IP barriers affect hydroxyurea products?

Hydroxyurea manufacturing is not inherently complex, but hazardous-drug controls raise operational requirements. Facilities must control dust, employee exposure, cross-contamination, cleaning validation, waste, and packaging operations. These controls can create a practical barrier for smaller manufacturers even when the formulation itself is simple.

The most important manufacturing issues are:

• High-containment powder handling
• Validated cleaning procedures
• Cross-contamination controls
• API particle-size control
• Blend uniformity for low-dose units
• Stability under temperature and humidity stress
• Light-protective packaging where required
• Accurate liquid dosing
• Stability after opening or reconstitution
• Child-resistant and tamper-evident packaging

These requirements can support trade-secret protection around process parameters and packaging operations. They rarely create exclusivity equivalent to a composition patent.

What licensing deals could create commercial value?

The most attractive licensing targets are not licenses to Hydrea itself. They are rights to enabling technologies:

• Pediatric liquid vehicles
• Taste-masking systems
• Hazardous-drug containment packaging
• Oral dosing syringes and unit-dose systems
• Stability-enhancing container closures
• Ready-to-use liquid manufacturing platforms
• Tablet technologies supporting flexible hydroxyurea dosing

A licensing transaction would be strongest where the technology has already been used with cytotoxic compounds or has regulatory precedent in pediatric oral medicines. A generic excipient supply agreement would provide lower strategic value than an exclusive formulation and device license tied to a specific hydroxyurea product.

What is the best commercial strategy for a new hydroxyurea product?

The strongest opportunity is a ready-to-use, pediatric-oriented oral liquid or a tablet-and-device system with documented dose flexibility. The product should be lactose-free, easy to administer, stable through the labeled use period, and packaged to reduce hazardous-drug exposure.

A practical development sequence is:

1. Select a target concentration that supports common weight-based doses.
2. Screen aqueous and suspension vehicles.
3. Optimize taste masking without compromising stability.
4. Establish container-closure compatibility.
5. Develop oral syringes and dose markings.
6. Generate extractables, leachables, stability, and microbiological data.
7. Determine the appropriate FDA pathway and reference product.
8. Build formulation, packaging, manufacturing, and use patents.
9. Position the product for pediatric hematology and hospital systems.
10. Protect supply through dual-source excipient and packaging qualification.

The commercial case is strongest when the product replaces pharmacy compounding and reduces dose-preparation burden. A simple reformulated capsule is unlikely to generate comparable value.

Key Takeaways

• Hydrea is a 500 mg hydroxyurea hard-gelatin capsule with a conventional excipient system.
• Its listed excipients include lactose, sodium phosphate dibasic, citric acid, and magnesium stearate.
• Foundational Hydrea and hydroxyurea exclusivity has expired; generic competition is established.
• Excipient substitution alone offers weak patent protection.
• The highest-value opportunity is a pediatric oral liquid with validated stability, taste masking, dose accuracy, and hazardous-drug controls.
• Non-gelatin and lactose-free capsules may support niche positioning but are unlikely to justify a substantial premium by themselves.
• New patent value is more likely in integrated formulation, packaging, dosing-device, manufacturing, and method-of-use claims.
• Manufacturing controls for cytotoxic drugs can create practical barriers even where legal exclusivity is weak.
• The most credible licensing targets are pediatric liquid platforms, containment packaging, dosing devices, and stability technologies.

FAQs About Hydrea Excipient and Formulation Opportunities

Can hydroxyurea capsules be opened and mixed with food?

Opening capsules may create dose-uniformity and occupational-exposure concerns. Any sprinkle presentation should be specifically developed, validated, labeled, and packaged for that use rather than relying on the legacy Hydrea capsule.

Is a lactose-free Hydrea equivalent commercially attractive?

A lactose-free version could address a defined patient preference, but lactose removal alone is unlikely to support strong pricing or patent protection. Its value increases when combined with pediatric dosing, a smaller capsule, or improved handling.

Can a hydroxyurea oral liquid receive FDA approval?

Yes. A liquid would require an appropriate regulatory pathway, quality specifications, stability data, microbiological controls, dosing-device validation, and labeling that addresses administration and hazardous-drug handling.

Does hydroxyurea have biosimilar competition?

No. Hydroxyurea is a small-molecule drug, so competing products are generics or reformulated products, not biosimilars.

What is the highest-value patent claim for a new hydroxyurea product?

A claim directed to a validated formulation and container system that delivers defined stability, dose uniformity, palatability, and handling performance is generally more defensible than a broad claim covering hydroxyurea with a routine excipient.

References

1. U.S. Food and Drug Administration. (n.d.). Hydrea (hydroxyurea) prescribing information.
2. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings, 2023. Centers for Disease Control and Prevention.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
5. U.S. Food and Drug Administration. (n.d.). Siklos (hydroxyurea) prescribing information.
6. U.S. Food and Drug Administration. (n.d.). Droxia (hydroxyurea) prescribing information.